Title:
QUINOLINOFURAN DERIVATIVE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/025298
Kind Code:
A1
Abstract:
Disclosed are a quinolinofuran derivative as shown in formula I or a pharmaceutically acceptable salt thereof, a pharmaceutically composition containing same, and a use thereof in preparing a drug for the prevention and/or treatment of MK2-mediated diseases. The definition of groups in the general formula is the same as that in the description.
Inventors:
WANG ZHONGLI (CN)
HAO XIN (CN)
LUO ZHIYANG (CN)
KUANG LIANG (CN)
LIU MENGLIN (CN)
HAO XIN (CN)
LUO ZHIYANG (CN)
KUANG LIANG (CN)
LIU MENGLIN (CN)
Application Number:
PCT/CN2022/115213
Publication Date:
March 02, 2023
Filing Date:
August 26, 2022
Export Citation:
Assignee:
REISTONE BIOPHARMA COMPANY LTD (CN)
International Classes:
C07D493/14; A61K31/551; A61P3/00; A61P9/00; A61P29/00; A61P35/00; A61P37/00
Domestic Patent References:
| WO2016044463A2 | 2016-03-24 | |||
| WO2014149164A1 | 2014-09-25 | |||
| WO2009010488A1 | 2009-01-22 |
Foreign References:
| CN110678471A | 2020-01-10 | |||
| US20200102327A1 | 2020-04-02 | |||
| US20210122762A1 | 2021-04-29 | |||
| US20200102325A1 | 2020-04-02 |
Other References:
ANDERSON, D.R. ; MEYERS, M.J. ; KURUMBAIL, R.G. ; CASPERS, N. ; PODA, G.I. ; LONG, S.A. ; PIERCE, B.S. ; MAHONEY, M.W. ; MOUREY, R: "Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 19, no. 16, 15 August 2009 (2009-08-15), Amsterdam NL , pages 4882 - 4884, XP026419101, ISSN: 0960-894X
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
Download PDF:
Previous Patent: METHOD FOR PREPARING QLED DEVICE, QLED DEVICE AND DISPLAY DEVICE
Next Patent: DATA FRAME FORMAT, CHIP COMMUNICATION METHOD, AND CHIP
Next Patent: DATA FRAME FORMAT, CHIP COMMUNICATION METHOD, AND CHIP